Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update

Reuters

Nov 28

Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update

Xlife Sciences AG provided an update on the planned combination between its portfolio company, VERAXA Biotech AG, and Voyager Acquisition Corp., a U.S.-listed special purpose acquisition company. VERAXA recently filed an amendment to its registration statement with the U.S. Securities and Exchange Commission following delays caused by a 43-day U.S. government shutdown. The extraordinary general meeting for VERAXA shareholders to approve the business combination is expected to be scheduled in December 2025. Xlife Sciences AG anticipates that VERAXA's listing on NASDAQ will be completed in the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2237500_en), on November 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2586278100"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586278100\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586278100?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586278100","market":"fut","top_or_hot":-1,"title":"Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xlife Sciences AG provided an update on the planned combination between its portfolio company, VERAXA Biotech AG, and <a href=\"https://laohu8.com/S/VACH\">Voyager Acquisition Corp</a>., a U.S.-listed special purpose acquisition company. VERAXA recently filed an amendment to its registration statement with the U.S. Securities and Exchange Commission following delays caused by a 43-day U.S. government shutdown. The extraordinary general meeting for VERAXA shareholders to approve the business combination is expected to be scheduled in December 2025. Xlife Sciences AG anticipates that VERAXA's listing on NASDAQ will be completed in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2237500_en), on November 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-28 20:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xlife Sciences AG provided an update on the planned combination between its portfolio company, VERAXA Biotech AG, and <a href=\"https://laohu8.com/S/VACH\">Voyager Acquisition Corp</a>., a U.S.-listed special purpose acquisition company. VERAXA recently filed an amendment to its registration statement with the U.S. Securities and Exchange Commission following delays caused by a 43-day U.S. government shutdown. The extraordinary general meeting for VERAXA shareholders to approve the business combination is expected to be scheduled in December 2025. Xlife Sciences AG anticipates that VERAXA's listing on NASDAQ will be completed in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2237500_en), on November 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VACH","symbol_name":"Voyager Acquisition Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDLQZ3Kz:1","article_id":"2586278100","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586278100","pubTimestamp":1764331995,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xlife Sciences AG provided an update on the planned combination between its portfolio company, VERAXA Biotech AG, and Voyager Acquisition Corp., a U.S.-listed special purpose acquisition company. VERAXA recently filed an amendment to its registration statement with the U.S. Securities and Exchange Commission following delays caused by a 43-day U.S. government shutdown. The extraordinary general meeting for VERAXA shareholders to approve the business combination is expected to be scheduled in December 2025. Xlife Sciences AG anticipates that VERAXA's listing on NASDAQ will be completed in the first quarter of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VACH":"Voyager Acquisition Corp"},"translate_title":"Xlife Sciences AG在SEC文件更新后推进VERAXA Biotech纳斯达克上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VACH":0.9},"content_text":"Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update\n    \n\n        Xlife Sciences AG provided an update on the planned combination between its portfolio company, VERAXA Biotech AG, and Voyager Acquisition Corp., a U.S.-listed special purpose acquisition company. VERAXA recently filed an amendment to its registration statement with the U.S. Securities and Exchange Commission following delays caused by a 43-day U.S. government shutdown. The extraordinary general meeting for VERAXA shareholders to approve the business combination is expected to be scheduled in December 2025. Xlife Sciences AG anticipates that VERAXA's listing on NASDAQ will be completed in the first quarter of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2237500_en), on November 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}